Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19
Status:
Completed
Trial end date:
2020-11-26
Target enrollment:
Participant gender:
Summary
In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of
pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome
information of a novel coronavirus (SARS-CoV-2) from these pneumonia patients and developed a
real-time reverse transcription PCR (real-time RT-PCR) diagnostic assay.
Given no specific antiviral therapy for COVID-19 and the ready availability of plitidepsin as
a potential antiviral agent, based on pre-clinical studies, this randomized, parallel and
proof of concept trial will evaluate the safety of three doses of plitidepsin in patients
hospitalized with COVID-19.